摘要
目的观察支气管哮喘急性发作应用扎鲁司特与布地奈德联合治疗的临床效果。方法对2006年11月～2011年11月于笔者所在科室治疗的160例支气管哮喘急性发作患者进行分析,随机分为A、B两组,每组80例,B组应用抗生素、氨茶碱以及β受体激动剂进行治疗,A组于B组基础上再应用扎鲁司特联合治疗,两组疗程均为14d。结果治疗后A组患者治疗前TNF-α与白介素6以及IgE含量同B组比较,差异有统计学意义(P<0.05);A组患者1秒量与1秒率的改善情况同B组比较,差异有统计学意义(P<0.05);A组患者喘息胸闷与咳嗽等症状的缓解情况同B组比较,差异有统计学意义(P<0.05),A组患者哮喘症状白天的发作次数与夜间的发作次数同B组比较,差异有统计学意义(P<0.05)。A组患者所用药物其不良反应的发生率同B组比较,差异无统计学意义(P>0.05)。结论支气管哮喘的急性发作患者应用扎鲁司特与布地奈德进行联合治疗,较单纯予以布地奈德进行雾化吸入的效果更为显著,安全可靠,应予推广。
Objective To observe the clinical effect of zafirlukast combined with budesonide in the treatment of bronchial asthma in acute exacerbation. Methods A retrospective analysis of clinical data of 160 cases with bronchial asthma in our hospital from November 2006 to November 2011.The patients were randomly divided into two groups（n=80）, group B was treated with antibiotics with aminophylline and [3 agonist, group A were treated by zafirlukast based on the treatment of group B,the course of each group were 14 days. Results There was a difference （P 〈 0.05） in TNF- ct and IL 6 before treatment between the two groups after 14 days of treatment, compared the improvement of FEV1 and FVC of two groups,had a differences significant （P 〈 0.05）; the breathing chest tightness and ease the cough and other symptoms of two groups had a differences significant （P 〈 0.05）; the attack number of day and night between the two group had a differences significant （P 〈 0.05）; the adverse effects rate of two group had no differences significant （P 〉 0.05）. Conclusion Zafirlukasl combined with budesonide in the treatment of bronchial asthma in acute exacerbation have a good effect than only use budesonide on atomization inhalation therapy, safe and reliable, and is worth popularizing.
出处
《中国医药科学》
2012年第19期52-53,共2页
China Medicine And Pharmacy
